Genetics: Chromosome 6 BTN2A2 and BTN3A3 (BTN2A1)

I am now up to my ears in grant reviewing
I am now up to my ears in grant writing :)

PS: with 3 Tier 1 DecodeME genes mentioned in the abstract... I am doing what I can to chase these leads within the bits that I understand and am pulling in experts for the bits that I don't, but we still really need more hands on this and more people being pulled in - i share your sense of gravity
 
Last edited:
I strongly agree that bringing in one or more experts on BTN should be a priority for the field. This really seems like a significant gene SNP in MECFS, with potential to point us toward the mechinism, and having someone with the relevant knowledge involved could really drive the field forward in a major way imo.
This guy's publications look really relevant! I hope someone can find the time to make the approach.

If no-one can find time for the forseeable, perhaps someone more scientifcally adept could summarise where we're at with the BTNs and I could draft an email around that summary? I think it should really be a scientist (or patient-scientist) who gets in touch if at all possible though.
 
Yes, but I think I would argue that when it comes to where the two main candidates would be around neurons again, so the same strategy as what James is looking at, or a shift in an innate immune cell population that could function anywhere so it doesn't matter too much.
Fair point. I think meningeal macrophages might be most promising--at the Invest in ME conference, Maureen Hanson made a good comment that meningeal involvement (at least in the acute phase) has been observed with both EBV and SARS-CoV-2. That population seems to have a robust IFN response per the linked study, and they could easily be the link between light/sound sensitivity in regular meningitis and ME/CFS.

This study is probably not a good model for LC but did show that spike protein is detectable in meningeal cells in mice [edit: and post-mortem human samples]--probably the same phenomenon of macrophages holding onto junk that can explain most of the gut biopsy findings from the viral persistence camp.

If BTN2A1 is involved in negatively regulating IL-1B, TNF, IL-6 etc. production from macrophages, I can see a link here between an initial immune insult and some kind of loop between neurons and meningeal macrophages.
 
Last edited:
Hi,
I used to work in the virology department in Würzburg and I am still PhD candidate in the graduate school there (and I have a Uni Würzburg mail account). However I do not know Thomas Herrmann and I am not on top of the BTN topic but if you think my connections there could be useful I am happy help make contacts.
I will also ask my PI if he has collaborations with him.
 
I will reach out to author of the autopsy studies that found reduced CRH and dystrophic microglia. When we met at a conference he was looking for other leads to support the relevance of microglia in ME/CFS. The BTN2A1 macrophage study I found might pique interest.

I am unfortunately also up to my eyeballs in grant applications so cannot do much more.
 
Hi,
I used to work in the virology department in Würzburg and I am still PhD candidate in the graduate school there (and I have a Uni Würzburg mail account). However I do not know Thomas Herrmann and I am not on top of the BTN topic but if you think my connections there could be useful I am happy help make contacts.
I will also ask my PI if he has collaborations with him.
Thank you for commenting! I think this is exactly what we need. I also don’t know much about BTN, but maybe a couple people here with more knowledge can help you draft an email? I’m curious to what your PI will say.
 
I had AI look to see if anyone at my local/province University had published on BTN. AI saved me a ton of time here, it found some researchers who I was able to write a polite email outlining the links in decodeME and the AstraZeneca data. I feel as though both strong genetic hits will be of interest and easier to point to in a short email. I kept my email short asking if they would like to know more while acknowledging their own work in relation to BTN.

Asking Claude to do an initial sweep of local organizations was extremely easy and time savings here. Possibly others can do this? I would not have Claude write them email, it is best if this comes from individuals. I find leveraging your local grassroots networks is quite effective. I always mention I am nearby them and believe in grassroots individuals can help!

Is this a good idea?
 
Hi,
I used to work in the virology department in Würzburg and I am still PhD candidate in the graduate school there (and I have a Uni Würzburg mail account). However I do not know Thomas Herrmann and I am not on top of the BTN topic but if you think my connections there could be useful I am happy help make contacts.
I will also ask my PI if he has collaborations with him.
keep us posted
 
The story is that BTNs recognise bacterial phosphoantigens. I am sceptical. I think they probably do something much more general, nothing to do with bacteria.

@Jonathan Edwards would you take a glance at this paper I posted yesterday:
I think a lot of it came down to this:
"Activation of γδ T-cells can be elicited by butyrophilin/butyrophilin-like molecules that are structurally similar to the immunosuppressive B7 family members. Yet how they regulate and coordinate αβ and γδ T-cell responses remains unknown. Here, we report that the BTN3A1 butyrophilin inhibits tumor-reactive αβ TCR activation by preventing segregation of N-glycosylated CD45 from the immune synapse."


Essentially this switch is messier than expexted!

Also this paper:

Butyrophilin 2A2 promotes T cell immunoregulation via CD45 phosphatase activation and protects against murine autoimmune glomerulonephritis and pregnancy loss​


Are these BTN's controlling T-cell response via CD45? These papers are bit over my head but the gist I get is that it does not require the phosphoantigens and are basically setting t-cell responsiveness. Any chance this effects other immune cells?
 
@Jonathan Edwards would you take a glance at this paper I posted yesterday:


Also this paper:

Butyrophilin 2A2 promotes T cell immunoregulation via CD45 phosphatase activation and protects against murine autoimmune glomerulonephritis and pregnancy loss​


Are these BTN's controlling T-cell response via CD45? These papers are bit over my head but the gist I get is that it does not require the phosphoantigens and are basically setting t-cell responsiveness. Any chance this effects other immune cells?
Is this a property solely of 2A2? Or could 2A1 do something like this too? Do we still think 2A1 is the most likely candidate in MECFS?
 
Are these BTN's controlling T-cell response via CD45? These papers are bit over my head but the gist I get is that it does not require the phosphoantigens and are basically setting t-cell responsiveness. Any chance this affects other immune cells?
The first paper you linked shows that BTN3A1 has different binding affinities and roles than BTN2A1, so unfortunately we can’t assume that any function of one BTN is shared by others.

Regardless, both of these studies you shared are reliant on the extracellular portion of BTNs binding to the extracellular portion of other surface molecules on T cells. Per the AZ analysis, all but one of the mutations in BTN2A1 occur in the cytosolic portion of the protein, indicating that it’s signaling within innate immune cells (or other cells with surface BTN2A1) that would matter more for ME/CFS.

What might be relevant here is if the regulatory effect of BTN2A1 on an innate immune cell occurs via T cells brushing up against them (or other cells that can travel in out and around tissue). In which case it would tell us to focus on either 1) innate immune cells that are in constant contact with T cells or 2) a specific point in time where T cells infiltrate a tissue during an initial triggering event, like an infection.

Might be interesting to see what happens in a BTN2A1 knockout mouse model during and after one of the infections associated with ME/CFS. It would be less than ideal because both SARS-CoV-2 and EBV require humanized mouse models that have different receptors than normal, so we might not be able to see specific organ involvement that occurs in humans. But might still reveal something.
 
Back
Top Bottom